Different infusion times of tislelizumab after liver cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving tislelizumab (an immunotherapy drug) at different infusion times after surgery can lower the chance of liver cancer coming back in people at high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with hepatocellular carcinoma (liver cancer) for the first time.
- You had surgery to remove your tumor and are at high risk of the cancer coming back (e.g., tumor larger than 5 cm, positive margin, or microvascular invasion).
- You have no signs of cancer spread outside the liver before or after surgery.
- Your liver function is good (Child-Pugh class A) and you haven't received any other cancer treatment after surgery.
- You are willing to use effective contraception during the study and for 4 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
This trial tests whether the immunotherapy drug Sintilimab, given after surgery, can help prevent liver cancer from coming back in people whose tumors had tiny blood vessel invasion. It is for patients who have fully recovered from surgery and have not had other cancer treatments before.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.